Tikomed: TikoMed's ILB mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target all neuroinflammation-driven diseases including ALS

VIKEN, Sweden, Aug. 31, 2022 /PRNewswire/ -- TikoMed, a biopharmaceutical company focused on harnessing the medical potential of the body's ability to self-repair and regenerate, today announced

Related Keywords

Sweden ,Anders Kristensson ,Kostenloser Wertpapierhandel ,Ann Logan ,Prnewswire Tikomed ,University Of Warwick ,Scientific Director ,Axolotl Consulting ,Regenerative Medicine ,Amyotrophic Lateral Sclerosis ,Traumatic Brain Injury ,Tikomed ,Emobilizes ,Modulates ,Growth ,Actors ,Trigger ,Cascade ,Neuroprotective ,Mechanisms ,Bible ,Target ,Neuroinflammation ,Riven ,Diseases ,Ncluding ,